Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
669-04-013 ISMRM Abstract

Thin-Slice Oblique Coronal Zoomed DWI on Ultra-High Gradient System: Improved Evaluation of Extrahepatic Cholangiocarcinoma

Primary: Body - Liver
Secondary: Diffusion - DWI/DTI/DKI
669-04-013 · Twists and Turns: Pancreas, Cholangio, and Bowel MRI · Thursday, 14 May, 2:35 PM–3:30 PM · Digital Posters Row J
Keywords: High Performance Gradients ZOOMit Cholangiocarcinoma Oblique coronal
Accepted
Lingsong Zhou 1, Beixuan Zheng1, Xianling Qian1, Xuhao Song1, Jili Chen1, Caixia Fu2, Mengsu Zeng1, Ruofan Sheng1
1Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
2MR Application Development, Siemens Shenzhen Magnetic Resonance Ltd., Shenzhen, China
Presenting Author: Lingsong Zhou

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557-588. doi:10.1038/s41575-020-0310-z [doi]
2. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi:10.1111/his.13975 [doi]
3. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int Off J Int Assoc Study Liver. 2019;39 Suppl 1:19-31. doi:10.1111/liv.14095 [doi]
4. Tabibian JH, Masyuk AI, Masyuk TV, O’Hara SP, LaRusso NF. Physiology of cholangiocytes. Compr Physiol. 2013;3(1):541-565. doi:10.1002/cphy.c120019 [doi]
5. Klempnauer J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer. 1997;79(1):26-34.
6. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261-280. doi:10.1038/nrgastro.2016.51 [doi]
7. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021-1031.e15. doi:10.1053/j.gastro.2011.12.005 [doi]
8. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3(1):18-34. doi:10.3978/j.issn.2304-3881.2014.02.05 [doi]
9. Gopal P, Robert ME, Zhang X. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Arch Pathol Lab Med. 2024;148(3):359-370. doi:10.5858/arpa.2022-0537-RA [doi]
10. Yoo J, Lee JM, Kang HJ, Bae JS, Jeon SK, Yoon JH. Comparison Between Contrast-Enhanced Computed Tomography and Contrast-Enhanced Magnetic Resonance Imaging With Magnetic Resonance Cholangiopancreatography for Resectability Assessment in Extrahepatic Cholangiocarcinoma. Korean J Radiol. 2023;24(10):983-995. doi:10.3348/kjr.2023.0368 [doi]
11. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet Lond Engl. 2021;397(10272):428-444. doi:10.1016/S0140-6736(21)00153-7 [doi]
12. Park HS, Lee JM, Choi JY, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol. 2008;190(2):396-405. doi:10.2214/AJR.07.2310 [doi]
13. Xin Y, Liu Q, Zhang J, et al. Hilar cholangiocarcinoma: Value of high-resolution enhanced magnetic resonance imaging for preoperative evaluation. J Cancer Res Ther. 2020;16(7):1634-1640. doi:10.4103/jcrt.JCRT_140_20 [doi]
14. Ryoo I, Lee JM, Park HS, Han JK, Choi BI. Preoperative assessment of longitudinal extent of bile duct cancers using MDCT with multiplanar reconstruction and minimum intensity projections: comparison with MR cholangiography. Eur J Radiol. 2012;81(9):2020-2026. doi:10.1016/j.ejrad.2011.06.007 [doi]
15. Pang L, Hu S, Dai W, Wu S, Kong J. Dilemma of the differential diagnosis of hilar cholangiocarcinoma and benign diseases: a single-center retrospective study. Carcinogenesis. 2021;42(3):442-447. doi:10.1093/carcin/bgaa125 [doi]
16. Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging JMRI. 2015;42(5):1165-1179. doi:10.1002/jmri.24810 [doi]
17. Brendle C, Martirosian P, Schwenzer NF, et al. Diffusion-weighted imaging in the assessment of prostate cancer: Comparison of zoomed imaging and conventional technique. Eur J Radiol. 2016;85(5):893-900. doi:10.1016/j.ejrad.2016.02.020 [doi]
18. Fan Q, Eichner C, Afzali M, et al. Mapping the human connectome using diffusion MRI at 300 mT/m gradient strength: Methodological advances and scientific impact. NeuroImage. 2022;254:118958. doi:10.1016/j.neuroimage.2022.118958 [doi]
19. Huang SY, Witzel T, Keil B, et al. Connectome 2.0: Developing the next-generation ultra-high gradient strength human MRI scanner for bridging studies of the micro-, meso- and macro-connectome. NeuroImage. 2021;243:118530. doi:10.1016/j.neuroimage.2021.118530 [doi]
20. Braitman LE. Statistical power analysis in medical research. Ann Intern Med. 1983;99(2):269-271. doi:10.7326/0003-4819-99-2-269 [doi]
21. Bischoff LM, Endler C, Krausewitz P, et al. Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience. Insights Imaging. 2024;15(1):287. doi:10.1186/s13244-024-01862-x [doi]
22. Lee H, Lee HH, Ma Y, et al. Age-related alterations in human cortical microstructure across the lifespan: Insights from high-gradient diffusion MRI. Aging Cell. 2024;23(11):e14267. doi:10.1111/acel.14267 [doi]
23. Watanabe M, Taguchi S, Machida H, et al. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. Eur Radiol. 2022;32(11):7513-7521. doi:10.1007/s00330-022-08813-4 [doi]
24. Finsterbusch J. Improving the performance of diffusion-weighted inner field-of-view echo-planar imaging based on 2D-selective radiofrequency excitations by tilting the excitation plane. J Magn Reson Imaging JMRI. 2012;35(4):984-992. doi:10.1002/jmri.23522 [doi]
25. Hu L, Wei L, Wang S, Fu C, Benker T, Zhao J. Better lesion conspicuity translates into improved prostate cancer detection: comparison of non-parallel-transmission-zoomed-DWI with conventional-DWI. Abdom Radiol N Y. 2021;46(12):5659-5668. doi:10.1007/s00261-021-03268-5 [doi]
26. Sim KC, Park BJ, Han NY, Sung DJ, Kim MJ, Han YE. Efficacy of ZOOMit coronal diffusion-weighted imaging and MR texture analysis for differentiating between benign and malignant distal bile duct strictures. Abdom Radiol N Y. 2020;45(8):2418-2429. doi:10.1007/s00261-020-02625-0 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/669-04-013